Filing Flows › C4 Therapeutics (CCCC) › Q3 2026 › vs Q2 2026
C4 Therapeutics (CCCC) Q3 2026 vs Q2 2026 (quarter over quarter)
C4 Therapeutics's revenue rose $1.8M (+28%) from $6.6M in Q2 2026 to $8.5M in Q3 2026.
C4 Therapeutics, Q3 2026: revenue $8.5M (-25% year over year), operating margin -290.5%, net loss $21.8M, operating cash flow −$26.0M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $8.5M | $6.6M | $1.8M | +28% |
| Other income, net | $2.8M | $2.8M | −$35K | -1% |
| Net loss | $21.8M | $23.6M | −$1.8M | -8% |
| Costs & expenses | $33.1M | $33.1M | $0 | 0% |
| Operating costs | $33.1M | $33.1M | $0 | 0% |
| Research & development | $24.8M | $24.5M | $332K | +1% |
| General & admin | $8.3M | $8.6M | −$332K | -4% |
| Operating cash sources | $29.3M | $4.9M | $24.4M | +497% |
| Depreciation | $320K | $292K | $28K | +10% |
| Share-based compensation | $3.0M | $3.0M | −$56K | -2% |
| Cash used in operations | $26.0M | $1.6M | $24.4M | 16× |
| Net loss absorbed | $21.8M | $23.6M | −$1.8M | -8% |
| Working capital & other | $7.4M | −$18.7M | $26.2M | — |
Questions
How much did C4 Therapeutics's revenue grow quarter over quarter in Q3 2026?
C4 Therapeutics's revenue rose $1.8M (+28%) from $6.6M in Q2 2026 to $8.5M in Q3 2026.